On November 30, 2018, on the occasion of the third anniversary of Beijing Haijinge Pharmaceutical Technology Co., Ltd.’s listing on the New Third Board, Haijinge Pharmaceutical held a “Work together to create the future together” at its headquarters in Beijing to warmly celebrate

On November 30, 2018, on the occasion of Beijing Haijinge Pharmaceutical Technology Co., Ltd. (stock code 834524 On the occasion of the third anniversary of the listing of Haikinge Pharmaceuticals on the New Third Board, Haikinge Pharmaceuticals held a "Work together to create the future - Warmly celebrate the third anniversary of the listing of Haikinge Pharmaceuticals on the New Third Board" at its headquarters in Beijing. At the event, Haijinge Pharmaceutical Chairman and President Mr. Qi Xuebing, Vice President Ms. Lang Guona, CFO Mr. Zheng Kai and some shareholders attended the celebration.

Figure 1: Chairman and President Qi Xuebing took a group photo with participating shareholders

At the celebration, Chairman and President Qi Xuebing introduced to the participating shareholders the development and changes of Haijinge Pharmaceuticals in the three years since it was listed on the New Third Board in 2015. Since the listing of the New OTC Market, Hainan has Kinge Pharmaceuticals has established a development strategy for the next five years. Within two years, it has comprehensively improved its corporate governance system and business development system, introduced industry talents, implemented employee equity incentives, and added capital operations from pure service operations. Leap-forward development, guided by altruistic culture and struggle culture, has strengthened the company's comprehensive strength and customer service capabilities. Heijinge Pharmaceutical is developing towards groupization, scale and globalization.

At the same time, Chairman and President Qi Xuebing also introduced to everyone the award-winning status of Heijinger Pharmaceuticals at the 2018 China Financial Summit Winter Forum held in Beijing on November 30. He said: "Haijinger Pharmaceuticals won two awards, the "Most Investment Value Award of the Year" and the "Most Growth Company of the Year" at this financial summit. This summit is based on corporate innovation capabilities, economic growth, and social contribution. , corporate culture, brand influence, industry status and other indicators, the organizing committee invited well-known institutions, experts, scholars, and media leaders to form a review committee, which passed Extensive social questionnaires, industry surveys and other methods are used to conduct quantifiable data comparisons based on the comprehensive evaluation system. The final list of winners is selected based on the principle of objectivity and fairness, and companies and figures who promote economic growth and social progress in the context of the new era are selected. As a model, Heijinger Pharmaceuticals relies on its excellent brand reputation in the CRO field and innovative development of business operations. Model, and rapid, healthy and stable development speed won two awards. This is Heijinger Pharmaceuticals once again occupying the focus of the financial and pharmaceutical industries after its Series A financing. It also shows that industry insiders and investors highly value the results of its efforts. Approval and recognition."

Figure 2: "Most Investment Value Award of the Year" and " Two awards for the "Most Promising Company of the Year"

Immediately afterwards, CFO Zheng Kai introduced to everyone the development and changes in the capital market after Heijinger Pharmaceuticals was listed on the New Third Board. The company's valuation reached hundreds of millions of yuan, and it successfully completed A This round of strategic financing of tens of millions of yuan has increased the company's market value and made full preparations for Series B financing. At the end of the

event, Chairman and President Qi Xuebing and Vice President Lang Guona cut the cake together and celebrated with the participating shareholders the third anniversary of the listing of Heijinger Pharmaceuticals on the New Third Board and the winning of two awards. In the future, Heijinger Pharmaceuticals will continue to standardize governance in accordance with the requirements of public companies, promote rapid and stable development of the company with customers as the center, create value for customers, provide a good platform for employees to grow and realize their own value, and achieve customers and employees!